Literature DB >> 26456771

Lymphotoxin-β receptor in microenvironmental cells promotes the development of T-cell acute lymphoblastic leukaemia with cortical/mature immunophenotype.

Mónica T Fernandes1,2, Marinella N Ghezzo1,2, André B Silveira3, Ravi K Kalathur1, Vanda Póvoa4, Ana R Ribeiro5,6,7, Sílvia R Brandalise3, Emmanuel Dejardin8, Nuno L Alves5,6, Jacques Ghysdael9,10,11, João T Barata4, José Andres Yunes3,12, Nuno R dos Santos1.   

Abstract

Lymphotoxin-mediated activation of the lymphotoxin-β receptor (LTβR; LTBR) has been implicated in cancer, but its role in T-cell acute lymphoblastic leukaemia (T-ALL) has remained elusive. Here we show that the genes encoding lymphotoxin (LT)-α and LTβ (LTA, LTB) are expressed in T-ALL patient samples, mostly of the TAL/LMO molecular subtype, and in the TEL-JAK2 transgenic mouse model of cortical/mature T-ALL (Lta, Ltb). In these mice, expression of Lta and Ltb is elevated in early stage T-ALL. Surface LTα1 β2 protein is expressed in primary mouse T-ALL cells, but only in the absence of microenvironmental LTβR interaction. Indeed, surface LT expression is suppressed in leukaemic cells contacting Ltbr-expressing but not Ltbr-deficient stromal cells, both in vitro and in vivo, thus indicating that dynamic surface LT expression in leukaemic cells depends on interaction with its receptor. Supporting the notion that LT signalling plays a role in T-ALL, inactivation of Ltbr results in a significant delay in TEL-JAK2-induced leukaemia onset. Moreover, young asymptomatic TEL-JAK2;Ltbr(-/-) mice present markedly less leukaemic thymocytes than age-matched TEL-JAK2;Ltbr(+/+) mice and interference with LTβR function at this early stage delayed T-ALL development. We conclude that LT expression by T-ALL cells activates LTβR signalling in thymic stromal cells, thus promoting leukaemogenesis.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  T-cell acute lymphoblastic leukaemia; lymphotoxin; lymphotoxin-beta receptor; tumour microenvironment; tumour-stromal interactions

Mesh:

Substances:

Year:  2015        PMID: 26456771     DOI: 10.1111/bjh.13760

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Evidence that TNF-β induces proliferation in colorectal cancer cells and resveratrol can down-modulate it.

Authors:  Constanze Buhrmann; Mina Yazdi; Bastian Popper; Parviz Shayan; Ajay Goel; Bharat B Aggarwal; Mehdi Shakibaei
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-19

2.  Lymphotoxin β receptor-mediated NFκB signaling promotes glial lineage differentiation and inhibits neuronal lineage differentiation in mouse brain neural stem/progenitor cells.

Authors:  Xiao Xiao; Raj Putatunda; Yonggang Zhang; Priya V Soni; Fang Li; Ting Zhang; Mingyang Xin; Jin Jun Luo; John R Bethea; Yuan Cheng; Wenhui Hu
Journal:  J Neuroinflammation       Date:  2018-02-20       Impact factor: 8.322

3.  A DNA-Methylated Sight on Autoimmune Inflammation Network across RA, pSS, and SLE.

Authors:  Xingqiang Wang; Dongyun Lei; Jie Ding; Shuang Liu; Li Tao; Fan Zhang; Jiangyun Peng; Jian Xu
Journal:  J Immunol Res       Date:  2018-08-12       Impact factor: 4.818

4.  Association between single nucleotide polymorphisms within HLA region and disease relapse for patients with hematopoietic stem cell transplantation.

Authors:  Ding-Ping Chen; Su-Wei Chang; Po-Nan Wang; Fang-Ping Hus; Ching-Ping Tseng
Journal:  Sci Rep       Date:  2019-09-24       Impact factor: 4.379

5.  Small molecule inhibition of Dynamin-dependent endocytosis targets multiple niche signals and impairs leukemia stem cells.

Authors:  Cedric S Tremblay; Sung Kai Chiu; Jesslyn Saw; Hannah McCalmont; Veronique Litalien; Jacqueline Boyle; Stefan E Sonderegger; Ngoc Chau; Kathryn Evans; Loretta Cerruti; Jessica M Salmon; Adam McCluskey; Richard B Lock; Phillip J Robinson; Stephen M Jane; David J Curtis
Journal:  Nat Commun       Date:  2020-12-04       Impact factor: 14.919

Review 6.  The Therapeutic Potential of Targeting NIK in B Cell Malignancies.

Authors:  Marco V Haselager; Eric Eldering
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.